LONDON (AP) -- Shares of drugmaker SkyePharma PLC dropped nearly 6 percent Monday after the company said it must provide the U.S. Food and Drug Administration with addition clinical data on its Flutiform asthma treatment in order to receive the go-ahead to market the drug.
